Factor VII Inhibitor Screen, Plasma
Use
This test is useful for detecting the presence of a specific inhibitor directed against coagulation factor VII. Such inhibitors may arise due to multiple exposures from transfusions in patients with deficiencies, certain disease states, or drug-induced conditions. The test involves measuring the percentage of the recovered factor after incubating patient plasma, normal pooled plasma, and their mixtures, which helps in identifying the effect of the inhibitor.
Special Instructions
The test is only orderable as part of a profile. It's recommended to follow the [Coagulation Guidelines for Specimen Handling and Processing](http://www.mayocliniclabs.com/it-mmfiles/Coagulation_Studies.pdf). For more information, see tests 7INHE, ALBLD, APROL.
Limitations
This test has been modified from the manufacturer's instructions and its performance characteristics were determined by Mayo Clinic in accordance with CLIA requirements. It has not been specifically cleared or approved by the FDA. Occasionally, results may be affected by a potent lupus-like anticoagulant, leading to false-positives.
New York Approved
Methodology
Automated Analyzer (Coagulation)
Biomarkers
LOINC Codes
- 81123-2
- 81123-2
Result Turnaround Time
1-3 days
Related Documents
For more information, please review the documents below
Specimen
Plasma
Volume
Not provided
Minimum Volume
2 mL
Collection Instructions
For more information see [Coagulation Guidelines for Specimen Handling and Processing](http://www.mayocliniclabs.com/it-mmfiles/Coagulation_Studies.pdf).
Causes for Rejection
Gross hemolysis, Gross lipemia, Gross icterus
Stability Requirements
| Temperature | Period |
|---|---|
| Frozen | 14 days |